Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-15 5:28 pm Unchanged | 2025-08-13 | 13D | Compass Therapeutics, Inc. CMPX | ORBIMED ADVISORS LLC | 15,219,994 8.900% | 0 (Unchanged) | Filing History |
| 2025-08-14 6:07 pm Purchase | 2025-06-30 | 13G | CytomX Therapeutics, Inc. CTMX | ORBIMED ADVISORS LLC | 8,461,500 5.400% | 8,461,500 (New Position) | Filing History |
| 2025-08-14 6:03 pm Sale | 2025-06-30 | 13G | NeuroPace, Inc. NPCE | ORBIMED ADVISORS LLC | 2,614,184 8.000% | -792,151 (-23.26%) | Filing History |
| 2025-08-14 6:00 pm Purchase | 2025-06-30 | 13G | Avalo Therapeutics, Inc. AVTX | ORBIMED ADVISORS LLC | 967,000 8.900% | 967,000 (New Position) | Filing History |
| 2025-08-14 5:56 pm Sale | 2025-06-30 | 13G | Verastem, Inc. VSTM | ORBIMED ADVISORS LLC | 1,333,333 2.400% | -1,529,115 (-53.42%) | Filing History |
| 2025-08-14 5:53 pm Purchase | 2025-06-30 | 13G | X4 Pharmaceuticals, Inc. XFOR | ORBIMED ADVISORS LLC | 134,947 1.700% | 134,947 (New Position) | Filing History |
| 2025-08-13 7:43 pm Purchase | 2025-08-11 | 13D | ArriVent BioPharma, Inc. Common Stock AVBP | ORBIMED ADVISORS LLC | 3,027,328 7.500% | 3,027,328 (New Position) | Filing History |
| 2025-07-30 9:28 pm Purchase | 2025-07-25 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 773,754 6.920% | 106,345 (+15.93%) | Filing History |
| 2025-07-24 5:44 pm Sale | 2025-07-22 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 132,473 4.250% | -111,405 (-45.68%) | Filing History |
| 2025-07-21 5:28 pm Sale | 2025-07-17 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 243,878 7.820% | -52,299 (-17.66%) | Filing History |
| 2025-07-09 8:06 pm Sale | 2025-07-07 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 296,177 9.500% | -36,323 (-10.92%) | Filing History |
| 2025-06-18 8:23 pm Purchase | 2025-06-14 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 667,409 16.710% | 667,409 (New Position) | Filing History |
| 2025-06-17 5:30 pm Purchase | 2025-06-16 | 13D | Enliven Therapeutics, Inc. ELVN | ORBIMED ADVISORS LLC | 7,918,163 13.400% | 7,918,163 (New Position) | Filing History |
| 2025-05-15 8:15 pm Purchase | 2025-03-31 | 13G | NeuroPace, Inc. NPCE | ORBIMED ADVISORS LLC | 3,406,335 10.500% | 3,406,335 (New Position) | Filing History |
| 2025-05-15 8:13 pm Purchase | 2025-03-31 | 13G | InspireMD, Inc. NSPR | ORBIMED ADVISORS LLC | 2,133,405 7.200% | 2,133,405 (New Position) | Filing History |
| 2025-05-15 8:09 pm Purchase | 2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC | ORBIMED ADVISORS LLC | 4,655,600 6.600% | 4,655,600 (New Position) | Filing History |
| 2025-05-15 6:46 pm Purchase | 2025-03-31 | 13G | Whitehawk Therapeutics Inc WHWK | ORBIMED ADVISORS LLC | 4,166,000 8.900% | 4,166,000 (New Position) | Filing History |
| 2025-05-15 6:41 pm Purchase | 2025-03-31 | 13G | Verastem, Inc. VSTM | ORBIMED ADVISORS LLC | 2,862,448 5.600% | 2,862,448 (New Position) | Filing History |
| 2025-05-14 8:49 pm Unchanged | 2025-05-12 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 12.200% | 0 (Unchanged) | Filing History |
| 2025-05-12 7:13 pm Purchase | 2025-05-09 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 15,252,867 14.500% | 15,252,867 (New Position) | Filing History |